Business Wire

XPENG-MOTORS

Share
XPENG Launches G9 SUV and P7 Sedan for Europe

XPENG (NYSE: XPEV and HKEX: 9868), today launched its two latest smart EV models for European markets: G9 flagship SUV, and the new P7 sports sedan. Both models, on show at eCar Expo in Stockholm Feb 3-5, are now available for order in Denmark, Norway, the Netherlands, and Sweden.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230202005580/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Premium electric smart sedan with sports car DNA (Photo: Business Wire)

“XPENG G9 and P7 bring a combination of superior styling, quality, performance and comfort, exemplifying our market-leading technology and innovation. Today also represents a significant milestone as we build our presence in Europe. We believe both vehicles deliver a new level of sophistication and a people-first mobility experience, and will be the electric vehicles of choice for many European customers,” said Brian Gu, Vice Chair and President of XPENG.

G9 features XPENG’s latest powertrain system, battery technology, and advanced driver assistance system (ADAS), fully complemented by a luxurious and immersive cabin experience. The new P7 - an upgraded version of P7 - combines its signature sports sedan profile with greater range, faster charging and a brand new smart cabin.

Faster Charging. Longer Range

XPENG’s new models bring some of the most powerful and advanced EV technology to Europe. XPENG G9 features a new powertrain system with 800 V Silicon Carbide (SiC) platform for ultra-fast charging of up to 300 kW, allowing drivers to add up to 100 km of range in just five minutes. This makes it possible to charge the 98 kWh battery from 10 % to 80% in just 20 minutes. G9 can travel up to 570 km WLTP on a single charge (RWD Long Range), exceptional for the battery size. G9 can be fitted with an electric tow bar, for up to 1,500 kg towed load, to suit European lifestyles.

The new P7 has been optimized with the maximum charging power of up to 175 kW, delivering fast charging from 10% to 80% in only 29 minutes. P7’s range has been improved, offering up to 576 km WLTP on a single charge (RWD Long Range). An electric tailgate and soft-closing doors are introduced for even greater comfort and convenience, along with a heat pump and heated steering wheel for more relaxing winter driving in the colder regions of Europe.

XPENG G9 and P7 are both engineered to meet E-NCAP five-star safety standards and stringent EU WVTA vehicle certification.

Superior Performance. Elegant Design

XPENG G9 and P7 boast superior performance with their advanced systems and elegant aerodynamic profiles, and are available in all-wheel-drive or rear-wheel drive configurations.

G9’s all-wheel drive version boasts up to 551 hp with a maximum torque of 717 Nm, powering acceleration from 0–100 km/h in just 3.9 seconds. The dual-chamber air spring system provides a wide range of stiffness adjustments to help the vehicle handle complex road conditions and ensure optimal ride comfort.

For the new P7, the all-wheel drive version accelerates from 0 to 100 km/h in just 4.1 seconds – outperforming even some sports car models. Brembo brakes also come as standard, giving drivers an extra level of control. All of this comes wrapped up in an exterior using XPENG's "Dynamic Aesthetics" design language that creates a more dynamic sports silhouette.

The new P7 is offered in a stunning range of colour styles, as well as an exclusive Wing Edition featuring scissors doors.

Both models adopt hidden door handles, with extremely low drag coefficients (0.236 for P7 and 0.272 for G9), for lower power consumption and extended range.

Comfort and Intelligence

The cabins of both vehicles use wraparound designs with high-quality finishing and materials to create a warm and comfortable environment. The ergonomically designed front seats feature heating and ventilation functions. To create an even more immersive cabin, both P7 and G9 can be configured with a Dynaudio sound system, producing up to 860 W and 2150 W respectively.

Both XPENG G9 and P7 come equipped with XPENG's proprietary Advanced Driver Assistance System, XPILOT, offering safety, driving, and parking support through a variety of smart functions. These functions are supported by 29 sensors including high-definition millimeter-wave radars, ultrasonic sensors, surround view and high perception cameras, enabling the vehicles to safely tackle multiple driving scenarios.

The upgraded in-car Xmart OS boasts a new 3D UI that supports English, Nederlands, Dansk, Norsk, and Svenska, depending on the market. Xmart OS also comes with the improved "Hey, XPENG" voice assistant, which can distinguish complex voice commands from all four zones of the cabin. These services are supported by wide infotainment screens and a library of in-car apps to assist, inform and entertain drivers and passengers.

G9 and P7 will also support easy and seamless over-the-air (OTA) updates that allow both software and firmware to be improved during normal use.

Expanding Service and Charging Networks

Delivery of the new models will capitalize on the opening of XPENG’s new Delivery and Service Centers in the key markets: at Lørenskog in Norway (opening February 2023), Badhoevedorp in the Netherlands, Stäket, Järfälla in Sweden and Hillerød in Denmark – all opening in the Q2 2023.

XPENG will also open additional authorized service locations with dedicated partners in key European countries by the end of 2023.

XPENG customers can access over 400,000 public charging stations in Europe, by collaboration with major European third-party charging operators and mobility service providers (Plugsurfing and Shell Recharge). With its new models, XPENG will provide third party home charger and installation services together with local partners, to offer customers a seamless easy charging experience.

Warranty

As a brand committed to product quality and offering better customer experiences, XPENG is proud to offer a five-year/120,000 km warranty* as standard for hassle-free ownership. For customers** ordering our new P7 sedan or G9 SUV between February 3 and December 31, 2023, the standard warranty will be extended to seven years/160,000 km from the date of delivery. This extended warranty is linked to the vehicle and is transferable when or if the vehicle is sold.

*For more information on the limited warranty policy, please refer to the warranty booklet.
**For more information on who is eligible for this extended warranty offer, please refer to the warranty booklet.

Pricing, Test Drive and Delivery

Expected starting prices* for the European version G9 are as follows

Model:

XPENG G9

Version

RWD Standard
Range

RWD Long
Range

AWD
Performance

Price(MSRP) - Norway (NOK)

499 900

569 900

639 900

Price(MSRP) - Sweden (SEK)

699 900

749 900

829 900

Price(MSRP) - Netherlands (EURO)

57 990

61 990

71 990

Price(MSRP) - Denmark (DKK)

479 900

549 900

599 900

Expected starting prices* for the new European version P7 are as follows

Model:

XPENG P7

Version

RWD Long Range

AWD Performance

Wing Edition

Price(MSRP) - Norway (NOK)

439 900

479 900

649 900

Price(MSRP) - Sweden (SEK)

599 900

669 900

799 900

Price(MSRP) - Netherlands (EURO)

49 990

59 990

69 990

Price(MSRP) - Denmark (DKK)

399 900

479 900

599 900

*All prices include VAT and exclude local taxes, registration fees, and delivery costs. Please contact local XPENG representatives for details.

Deliveries for the new P7 will begin in June and G9 deliveries are expected to commence in September.

Customers can contact XPENG’s experience stores (Oslo, The Hague, Stockholm, Copenhagen) for test drive schedules. For more information about the G9 and P7, please visit the dedicated local XPENG websites:

https://heyxpeng.com/no/p7
https://heyxpeng.com/se/p7
https://heyxpeng.com/dk/p7
https://heyxpeng.com/nl/p7
https://heyxpeng.com/no/g9
https://heyxpeng.com/se/g9
https://heyxpeng.com/dk/g9
https://heyxpeng.com/nl/g9

Presskit (visual assets and specs) link

Follow us:
XPENG Twitter
XPENG LinkedIn
XPENG Facebook
XPENG Instagram
XPENG TikTok
XPENG YouTube

About XPeng Inc.

XPeng is a leading Chinese Smart EV company that designs, develops, manufactures, and markets Smart EVs that appeal to the large and growing base of technology-savvy middle-class consumers. Its mission is to drive Smart EV transformation with technology and data, shaping the mobility experience of the future. In order to optimize its customers’ mobility experience, XPeng develops in-house its full-stack advanced driver-assistance system technology and in-car intelligent operating system, as well as core vehicle systems including powertrain and the electrical/electronic architecture. XPeng is headquartered in Guangzhou, China. In 2021, the Company established its European headquarters in Amsterdam, along with other dedicated offices in Copenhagen, Munich, Oslo, and Stockholm. The Company’s Smart EVs are mainly manufactured at its plant in Zhaoqing, Guangdong province. For more information, please visit https://heyxpeng.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005580/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye